Phiskin Raises $17 Million For China Aesthetic Clinics

PhiSkin, a Shanghai aesthetic medical provider, raised $17 million in a Series B round, led by Legend Capital of China and joined by Ares Management, a Los Angeles alternative asset manager. Founded in 2012, PhiSkin offers minimally invasive treatments that include injection of aesthetic products, laser treatment, double eyelid surgery and other non-surgical beauty treatments. The company already has clinics and beauty centers in Shanghai, Beijing, Ningbo and Hangzhou, with plans to expand to 10 centers by the end of 2017 and 38 by 2019.